From Aloe Leaf to Antidepressant: Aloe-Emodin Takes Aim at the RANBP9 Protein

A small molecule that has quietly travelled from the aloe leaf into the pages of Molecular Diversity may have just acquired a new job title: antidepressant lead compound. In a study published on 29 August 2026, researchers at Guangzhou University of Chinese Medicine and Linyi People’s Hospital in China report that aloe-emodin, a naturally occurring anthraquinone long studied for its effects on the heart, the kidneys and the brain, reverses key chemical signatures of depression in cells and in chronically stressed rodents. More striking is how the compound appears to work. Using a battery of target-identification techniques, the team shows that aloe-emodin binds a scaffold protein called RANBP9 with a dissociation constant of 716 nanomolar, anchors itself to a specific histidine residue, and then steers the protein toward the cell’s waste-disposal machinery for destruction. The finding, the authors conclude, suggests that RANBP9 may serve as a promising target for developing a new kind of antidepressant drug.

Hundreds of millions of people worldwide live with depressive disorders, and treatment-resistant cases remain a stubborn clinical problem. Yet most prescriptions written for the condition still trace their logic to the monoamine hypothesis, the decades-old idea that low serotonin or norepinephrine underlies low mood. That framework produced selective serotonin reuptake inhibitors and their relatives, drugs that help many patients but often take weeks to act and leave a substantial fraction of people without adequate relief. The past decade has complicated the picture considerably. The rapid antidepressant effect of ketamine, a blocker that acts on N-methyl-D-aspartate receptors, redirected scientific attention toward glutamate, the brain’s principal excitatory neurotransmitter, and toward the receptors that respond to it. But ketamine and its nasal-spray cousin esketamine carry their own baggage: dissociative side effects, abuse potential and safety concerns that European regulators continue to mine from pharmacovigilance databases. The field is therefore hunting for molecules that can tame pathological glutamate signalling more gently, and for new proteins at which such molecules could be aimed.

That is where excitotoxicity enters the story. NMDA receptors are calcium-permeable channels that sit at the heart of synaptic plasticity, and when they are overactivated they admit floods of calcium ions into neurons. The resulting calcium overload disrupts mitochondrial function, activates death-signalling enzymes and pushes cells toward apoptosis, a form of programmed suicide. One early amplifier of this damage is CaMKII, a calcium- and calmodulin-dependent kinase that, once autophosphorylated, can sustain its own activity long after the initial stimulus has passed, converting a transient calcium spike into a lasting toxic signal. Farther downstream, the destruction becomes legible in the nucleus, where the DNA-repair enzyme PARP is cleaved into diagnostic fragments, a classic molecular signature of apoptosis. Excitotoxicity of this kind has been implicated in stroke, Alzheimer’s disease and other neurological disorders, and a growing body of work argues that it is also a core pathological mechanism in depression, one that today’s medications barely touch.

Aloe-emodin makes an unlikely protagonist for this story. The molecule, an anthraquinone carrying hydroxyl and hydroxymethyl groups on its rigid three-ring core, is found in aloe and in other medicinal plants, including Cassia species whose seeds are a staple of traditional Chinese medicine. Recent years have produced a string of laboratory studies attributing protective effects to it against radiation-induced heart disease, chronic kidney fibrosis and Alzheimer’s-like pathology, in some cases through mechanisms involving protein lactylation, the PI3K signalling pathway or mitochondrial quality control. Because several of these reports pointed to the compound’s ability to shield cells from chemical and oxidative stress, the team, led by first author Yangyang Yang and corresponding authors Huaiqing Lv and Fengyuan Che, asked a sharper question: could aloe-emodin counter excitotoxicity directly, and could it do so by engaging a specific protein target rather than through vague, multi-target scavenging?

The first test was straightforward neurochemistry in a dish. The researchers challenged cells with N-methyl-D-aspartate, the agonist that forces NMDA receptors wide open and reproduces the calcium-driven damage seen in disease. Aloe-emodin reversed the injury in a dose-dependent manner: cell viability recovered, apoptosis fell, and leakage of lactate dehydrogenase, a standard marker of membrane damage, declined. Measurements of intracellular calcium confirmed that the compound eased the overload, and western blotting showed that NMDA-induced autophosphorylation of CaMKII, the self-amplifying kinase signal described above, was attenuated. The clean dose dependence hinted at a specific molecular interaction rather than a nonspecific buffering effect. The pattern matters because it places the compound’s action at or near the receptor-proximal signalling cascade where the toxicity begins, rather than merely mopping up reactive oxygen species after the damage is done. To see whether the same logic held in a living brain, the team next moved to an animal model of depression.

The model was chronic unpredictable mild stress, or CUMS, a widely used paradigm in which rodents are exposed for weeks to rotating mild stressors such as altered light cycles, damp bedding, crowding and restraint until they develop despair-like behaviour and loss of pleasure resembling core symptoms of human depression. In stressed animals treated with aloe-emodin, depression-like behaviours were significantly ameliorated. Beneath the behaviour, the molecular picture shifted as well. Inflammatory responses were suppressed, with the study tracking pro-inflammatory cytokines including interleukin-6, interleukin-1β and tumour necrosis factor-α. Oxidative stress receded, visible in falling levels of malondialdehyde, a lipid-peroxidation by-product, alongside recovering antioxidant defences such as glutathione. Levels of cleaved-PARP, the apoptosis signature, were downregulated in tissue, and histological examination reflected the biochemical recovery. The compound, in short, acted on the behavioural, inflammatory, oxidative and apoptotic faces of the model at once.

The pivotal question — what exactly does aloe-emodin bind? — was answered with a four-technique interrogation. First, the chemists attached a biotin handle to aloe-emodin and used the tagged molecule as bait in pull-down assays, fishing bound proteins out of cell lysates and identifying them by liquid chromatography–tandem mass spectrometry. Among the enriched candidates was RANBP9, also known as RanBPM, a multi-domain scaffold protein previously implicated in cell-signalling regulation and in Alzheimer’s disease pathways. Three orthogonal methods then confirmed the liaison. In the cellular thermal shift assay, or CETSA, RANBP9 resisted heat-induced denaturation in the presence of the drug, a fingerprint of direct binding inside intact cells. In DARTS, drug affinity responsive target stability, the protein became harder for proteolytic enzymes to digest when aloe-emodin was present, because the bound ligand shielded it. And surface plasmon resonance, an optical technique that follows binding in real time on a sensor chip, returned a dissociation constant of 716 nanomolar, a respectable affinity for a natural product engaging a brand-new target.

Computational chemistry supplied the atomic-level detail. Molecular docking placed aloe-emodin inside a pocket on RANBP9, and molecular dynamics simulations, in which the protein–ligand complex is simulated in an explicit water box under near-physiological conditions, showed the binding pose remaining stable across the trajectory, with the free-energy landscape settling into a single dominant basin, a sign that the complex prefers one well-defined binding mode. The decisive contact involved the histidine at position 332: aloe-emodin engaged the His332 residue selectively, and the simulated interaction network converged on that point of attachment. Selectivity matters here. Scaffold proteins such as RANBP9 present many shallow surfaces and few deep, well-formed pockets, which is one reason they have long been labelled undruggable. A small, plant-derived molecule that recognises one specific residue with sub-micromolar affinity is, on its own terms, a proof of concept that such proteins can be engaged chemically — and engaged gently, without a covalent warhead.

Perhaps the most consequential finding concerns what aloe-emodin does to RANBP9 after binding it. Rather than simply occupying the protein, the compound promoted RANBP9’s degradation through the ubiquitin–proteasome pathway, the cell’s standard machinery for tagging unwanted proteins with chains of ubiquitin and shipping them to the proteasome for demolition. The facilitator is CHIP, the C-terminus of Hsc70-interacting protein, an E3 ubiquitin ligase that confers specificity on the tagging process. Aloe-emodin, the study shows, strengthens the interaction between RANBP9 and CHIP, effectively acting as a molecular glue that hands the scaffold protein to its executioner. The result resonates with one of the liveliest currents in modern drug discovery: targeted protein degradation, the strategy behind PROTACs and molecular glues, which has lately been extended to tau, alpha-synuclein and other proteins implicated in neurodegenerative disease. RANBP9 itself has prior form in this territory, with earlier work linking it to amyloidogenic processing of the Alzheimer’s-associated APP protein and to enhanced tau pathology through chaperone complexes.

Finally came the causality test. When the researchers knocked RANBP9 down with small interfering RNA, aloe-emodin’s protection of cell viability and its suppression of apoptosis were significantly weakened, demonstrating that the compound’s anti-excitotoxic activity is RANBP9-dependent. The result contains an apparent paradox — a drug whose benefit requires the very protein it destroys — and the most economical reading is that the binding event itself is what matters: aloe-emodin must engage RANBP9 and recruit CHIP before the protective programme can unfold, so removing the target removes the drug’s foothold. Much remains to be established. The evidence rests on cell models and a rodent stress paradigm; the pharmacokinetics, brain penetration, dosing and long-term safety of aloe-emodin in a depression context are untested; and clinical translation of degradation-based chemistry is still in its infancy. But the study hands the field two concrete assets: a natural product with a chemically validated protein target, and a new name on the shortlist of glutamate-side antidepressant targets — RANBP9, histidine 332 and all.